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EDITORIAL
Should We Recommend Surgery to Patients with Limited
Small Cell Carcinoma of the Esophagus?
Aminah Jatoi, MD,* and Robert C. Miller, MD†
In this issue of the Journal of Thoracic Oncology, Lv et al.1 describe what seems to bethe largest, clinical experience to date of patients with small cell carcinoma of the
esophagus: a 126-patient report. This experience encompasses 20 years of patient care at
the Cancer Hospital of Peking Union Medical College from 1985 though 2005. Before this
publication, clinical decision-making for patients with small cell carcinoma of the
esophagus had been forced to rely upon single case reports and much smaller case series.
Indeed, several years ago, McFadden et al.2 provided a “review of the 129 cases reported
in the world literature”–a descriptive phrase that further underscores the seminal nature of
the data published in this issue of the Journal.
Thus, these authors are in a unique position to begin to provide insight into a
fundamental, therapeutic question: Should we recommend surgery to patients with limited
stage small cell carcinoma of the esophagus? Published case reports and small case series
have not been able to yield a consensus opinion in response to this question. Now,
however, Lv et al. provide recommendations that include a conspicuous absence of a
surgical approach: “Small cell esophageal cancer is a systemic disease . . .. Systemic
therapy, based on chemotherapy and radiotherapy, is recommended.” Their data bolster
their recommendation. Among 126 patients, 84 underwent surgery, and 79 underwent an
esophagectomy, including 64 with an R0 resection, 3 with an R1 resection, and 12 with
an R2 resection. There were two surgery-related deaths. Importantly, in a multivariate
analysis, favorable independent prognostic factors included earlier tumor stage and the
administration of chemotherapy–but not surgery. Based on these findings, the authors
question the role of surgery in the management of limited small cell carcinoma of the
esophagus.
As we further discuss this report, five points on study design merit mention. First,
one might wonder whether the variable “surgery: yes versus no” should instead have
denoted the type of resection achieved. In our opinion, this variable is well formulated in
its present form because it avoids the bias of selecting the best surgical subset. Moreover,
from a practical standpoint, this dichotomous variable captures the starkly black and white
decision of whether to take a patient to the operating room or not. Second, a randomized
trial, as opposed to a retrospective study, as reported here, would have provided more
reliable data on the role of surgery. The rarity of small cell carcinoma of the esophagus
makes it unlikely, however, that such a randomized trial will ever be conducted. Third,
this 126-patient study seems to be the largest to date, but even this sizable experience
lacks the power to detect a subtle improvement in survival with the addition of surgery
to an already potentially curative approach. Although compelling, this lack of a
surgical survival advantage does not provide definitive evidence of its nonexistence.
Fourth, in the study reported here, staging does not seem to have used present day,
state-of-the-art techniques such as the customary computerized tomography, routine
radioisotope bone scans, and mandatory magnetic resonance imaging of the brain.
Therefore, some surgical patients may have had unrecognized metastatic disease; and,
in this context, surgery may not have proven itself to be a statistically significant
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prognostic factor. Finally, although the number of patients
in this report is a major strength, the implications of so
many patients with such a rare malignancy being diag-
nosed and treated at a single institution remain unclear. Is
the biology of small cell carcinoma of the esophagus in
this report the same as it is elsewhere around the world?
TABLE 1. Previous Reports
Study n 1-yr or Median Survival Comments/Observations
Chin et al.6 12 34.7 mo All patients received chemotherapy, and some also received radiation. Seven
patients lived beyond a year, with 3 patients living 3.5, 4, and 4.5 yr.
Ku et al.7 25 19.8 mo Of the 6 long-term survivors (survival 5 yr), only 1 had received surgery; all
received chemotherapy and radiation.
Sun et al.8 73 51% The 4 patients who survived more than 10 yr had received postoperative
chemotherapy.
Yun et al.9 21 Not reported; 2-yr survival: 29% Three patients lived greater than 1 yr with chemotherapy and radiation; 2 lived
greater than 4 yr with esophagectomy, chemotherapy, and radiation.
Yau et al.10 10 8 mo Three patients received chemotherapy and radiation with survivals of 62, 34,
and 17 mo. All other patients lived under a year.
Koide et al.11 10 Not reported All 9 patients with limited disease received surgery and chemotherapy. Five
patients lived 18 mo.
Hudson et al.12 16 13.2 mo Six patients received chemotherapy and radiation and lived between 9 (still
alive at time of report) and 104 mo (still alive at time of report).
Yuan et al.13 33 41% This article is not in English, and therefore we are unable to know if
multimodality had been used in all patients.
Hosokawa et al.14 14 7.7 mo All 5 patients who underwent only esophagectomy, developed “early relapse.”
Among 9 patients who received chemotherapy with or without radiation,
“two have survived more than 2 yr.”
Nemoto et al.15 20 44% Three long-term survivors, who lived longer than 5 yr, received surgery,
chemotherapy, and radiation.
Pantvaidya et al.16 18 6 mo The only long-term survivor (48 mo) had received chemotherapy, surgery, and
radiation.
Lam et al.17 20 3.4 mo Long term survivors include one patient who underwent a palliative resection
with no chemotherapy and lived 1.8 yr; another who underwent a “curative”
resection, chemotherapy, and radiation and then lived 6 yr; another who
received chemotherapy and radiation and lived 1.4 yr; and a 4th who
received only a curative resection and lived 2 yr.
Bennouna et al.18 10 15.5 mo Long term survivors include one patient who received chemotherapy and
radiation and lived 19 mo; another who received chemotherapy and
radiation and lived 18 mo; another who received chemotherapy and
radiation and lived 19 mo; a third who received only surgery and died at 13
mo; and a 4th who received surgery, chemotherapy and radiation and
remained alive at last report at 18 mo.
Wang et al.19 47 5-yr survival rate 7.5% This article was not published in English, and so details are not available. The authors
also were from the Peking Union Medical College. All patients underwent surgery,
and postoperative chemotherapy was given to an unspecified subgroup.
Nishimaki et al.20 13 31% and 10 mo, respectively Long term survivors include one patient who received chemotherapy and
surgery and lived 106 mo; another who received surgery and chemotherapy
and lived 64 mo, and a third who underwent a “palliative” resection with no
chemotherapy and lived 34 mo.
Li et al.21 42 Not reported; mean survivals: 11.2
mo with surgery and 22.8 mo
with radiation
This study was not published in English. It is unclear what therapy in addition
to either surgery and/or radiation was provided.
Craig et al.22 16 Not reported Seven patients underwent surgery. One also received postoperative
chemotherapy and remained alive at the time of report at 96 mo. Another
died at 34 mo after surgery and adjuvant laser therapy.
Huncharek et al.23 13 23% No patients underwent surgery, but one patient who received chemotherapy
and radiation remained alive at 2 yr with no evidence of disease.
Law et al.24 11 3.1 mo Five patients had surgery, but the authors conclude, “Small cell carcinoma of
the esophagus should be regarded as a systemic disease, and multimodality
therapy, including chemotherapy, should be used.”
Chen, 25 10 50% and 15.2 mo, respectively This article was not in English, but all patients underwent surgery. No
comment is made on the use of other treatment modalities.
Nichols et al.26 11 7.5 mo Two patients underwent surgery followed by chemotherapy in both and whole
brain radiation in one. One of these patients lived for 8 mo (still alive at
time of report), and one was lost to follow-up.
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Are the conclusions from this study truly able to be
generalized? These questions cannot be answered. All the
same and at the very least, the findings from Lv et al. begin
to raise doubts about whether surgery should be an essen-
tial component of therapy for patients with this disease.
Such doubts have precedent. First, despite a sizable
literature that espouses surgery for patients with small cell
carcinoma of the esophagus, there is no question that
patients can be cured without it. In our review of 21
published, accessible case series, each comprising 10 or
more patients with small cell carcinoma of the esophagus
and each with a focus on therapy, a small group of
long-term survivors achieved such status without surgery
(Table 1). Any hint that patients who received surgery,
chemotherapy, and radiation lived longer may reflect noth-
ing more than a selection bias that resulted in more
aggressive therapy having been prescribed to fitter patients
who carried a better pretreatment prognosis. Clearly, how-
ever, surgery is not essential for cure. Second, parallel data
from patients with small cell carcinoma of the lung indi-
cate that a combination of chemotherapy and radiation
alone can cure a small subgroup of patients.3 Indeed, the
standard of care for patients with small cell carcinoma of
the lung is concomitant chemotherapy and radiation with
only a few exceptions. Third, other parallel data demon-
strate that even patients with locally advanced esophageal
cancer with the more typical squamous or adenocarcinoma
histologies can be cured without surgery. Cooper et al.4
showed that 26% of patients lived for 5 years after having
received only chemotherapy and radiation. Hence, the
suggestion from Lv et al. that surgery need not be an
integral part of the standard of care for patients with
limited small cell carcinoma of the esophagus is not
exceptional and therefore seems plausible.
Of further importance, when one scrutinizes compara-
tive risks and benefits, concerns emerge about the routine use
of surgery. The authors described median survivals of 5, 5.3,
17, and 16 months in patients treated with surgery alone,
surgery plus radiation, surgery plus chemotherapy, and sur-
gery plus both chemotherapy and radiation, respectively. As
a benchmark, the median survival for the 126-patient group
as a whole was 12.5 months, a reflection of the inclusion of
all tumor stages. In effect, the median survival remained
under 18 months for all surgically-treated patients. Yet, the
recovery period after esophagectomy can exhaust more than
half–if not all–of this life expectancy. Blazeby et al.5 reported
that among cancer patients, quality of life was worse at 6
weeks after an esophagectomy than it had been preopera-
tively, and most quality of life indicators improved to their
preoperative level only after 9 months. Although patients felt
better from an emotional standpoint after the extirpation of
their tumor, their degree of fatigue, physical functioning, and
global quality of life took almost a full year to recover to
baseline. Put simply, for many surgically-treated patients,
who live only a few months, their entire remaining life can be
consumed by convalescence.
So, should we recommend surgery to patients with
limited stage small cell carcinoma of the esophagus? The
answer to this question requires a discussion with patients
about the modest but potentially curative effects of a nonsur-
gical approach. This discussion should also inform patients of
the dearth of sound comparative data that have demonstrated
a survival advantage when surgery is combined with other
potentially curative approaches. Finally, this discussion
should go on to underscore the prolonged negative impact of
esophagectomy on quality of life. Thus, decision-making
requires putting aside the scalpel–if only temporarily–and
then, as always, candidly and comprehensively discussing
with patients the spectrum of therapeutic options and their
consequences. We anticipate that these discussions will often
give rise to a nonsurgical approach.
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